// App-Quantinova.ai

PB2420 : Rivaroxaban versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients

Researchers

Presenter

  • O.S. Costa

Principal Investigators

  • J. Beyer-Westendorf

  • V. Ashton

  • D. Milentijevic

  • K.T. Moore

  • T.J. Bunz

  • C.I. Coleman

Medical Centers

  • University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, United States

  • Hartford Hospital, Evidence Based Practice Center, Hartford, United States

  • University Hospital, Thrombosis Unit, Dresden, Germany

  • Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States

  • R&D, Janssen Pharmaceuticals, Inc., Titusville, NJ, United States

  • New England Health Analytics LLC, Granby, United States

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Body mass index

Drug/Treatment

  • rivaroxaban

  • Warfarin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved